Reducing CVD risk in individuals with obesity is therefore a critical public health priority, highlighting the potential role of glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) based therapies in addressing both obesity and its related cardiovascular complications. Here, GLP1R is linked to Obesity.